Psychedelic and ketamine research trials in France
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
21 registered studies are counted in France. By compound: 6 psilocybin, 1 MDMA and 14 ketamine. By registry status: 5 recruiting, 2 not yet recruiting, 1 active, not recruiting, 9 completed, 1 withdrawn and 3 status not reported. By phase: 3 phase 2, 5 phase 3, 6 not applicable and 7 not reported. Reported start years run from 2012 (earliest) to 2026 (latest). Studies are linked to 15 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
7 of the 21 counted studies are listed in the registry as recruiting (5) or not yet recruiting (2), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms | NCT07638553 | Recruiting | Phase 3 | 2026-06-01 | Centre Hospitalier Universitaire de Nīmes, Bayonne |
| Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study | NCT07391332 | Not yet recruiting | Phase 2 | 2026-04-01 | Nantes University Hospital, Nantes |
| Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder | NCT07099534 | Not yet recruiting | Phase 2 | 2025-11-01 | University Hospital, Toulouse, Toulouse |
| Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ) | NCT07210112 | Recruiting | Phase 2 | 2025-10-08 | Centre Hospitalier St Anne, Paris |
| Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients | NCT06508710 | Recruiting | Phase 3 | 2024-10-20 | Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicêtre |
| Belief Updating in Treatment Resistant Depression | NCT05577247 | Recruiting | Not reported | 2024-05-13 | Assistance Publique - Hôpitaux de Paris, Paris |
| Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine | NCT06630065 | Recruiting | Not applicable | 2023-03-13 | Centre Hospitalier St Anne, Paris |
At a glance
- 21 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 6 |
| MDMA | 1 |
| Ketamine | 14 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 5 | 24% |
| Not yet recruiting | 2 | 10% |
| Active, not recruiting | 1 | 5% |
| Completed | 9 | 43% |
| Withdrawn | 1 | 5% |
| Status not reported | 3 | 14% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 2 | 3 | 14% |
| Phase 3 | 5 | 24% |
| Not applicable | 6 | 29% |
| Not reported | 7 | 33% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 11 |
| 2020 to 2023 | 5 |
| 2015 to 2019 | 3 |
| 2010 to 2014 | 2 |
All counted studies
All 21 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms | NCT07638553 | Recruiting | Phase 3 | 2026-06-01 | Centre Hospitalier Universitaire de Nīmes, Bayonne |
| Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study | NCT07391332 | Not yet recruiting | Phase 2 | 2026-04-01 | Nantes University Hospital, Nantes |
| Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder | NCT07099534 | Not yet recruiting | Phase 2 | 2025-11-01 | University Hospital, Toulouse, Toulouse |
| Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ) | NCT07210112 | Recruiting | Phase 2 | 2025-10-08 | Centre Hospitalier St Anne, Paris |
| Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures | NCT06647056 | Completed | Not applicable | 2024-12-19 | Centre Hospitalier Universitaire de Nīmes, Nîmes |
| Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia | NCT07199179 | Active, not recruiting | Not reported | 2024-11-24 | University Hospital, Montpellier, Montpellier |
| Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression | NCT06650800 | Completed | Not applicable | 2024-11-19 | Centre Hospitalier Universitaire de Nīmes, Nîmes |
| Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients | NCT06508710 | Recruiting | Phase 3 | 2024-10-20 | Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicêtre |
| Belief Updating in Treatment Resistant Depression | NCT05577247 | Recruiting | Not reported | 2024-05-13 | Assistance Publique - Hôpitaux de Paris, Paris |
| Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State | NCT06133309 | Completed | Not applicable | 2024-03-19 | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Toulon |
| Psilocybin in Alcohol Use Disorder With Comorbid Depression | NCT06235411 | Completed | Not applicable | 2024-02-05 | Centre Hospitalier Universitaire de Nīmes, Nîmes |
| Sustained Ketamine Effectiveness for Suicidal Ideation | NCT06806475 | Completed | Not reported | 2023-12-01 | University Hospital, Montpellier, Montpellier |
| Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine. | NCT05949554 | Withdrawn | Not reported | 2023-09-01 | Assistance Publique - Hôpitaux de Paris, Colombes |
| Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine | NCT06630065 | Recruiting | Not applicable | 2023-03-13 | Centre Hospitalier St Anne, Paris |
| Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI | NCT05530668 | Completed | Not reported | 2022-04-11 | University Hospital, Strasbourg, France, Strasbourg |
| Addiction in Intensive Cardiac Care Units | NCT05063097 | Status not reported | Not reported | 2021-04-06 | Assistance Publique - Hôpitaux de Paris, Paris |
| Ketamine's Efficiency in the Treatment of Chronic Pain: Kynurenin Pathway | NCT03513822 | Status not reported | Phase 3 | 2018-02-16 | Redar, Garches |
| OBSERVATIONAL STUDY OF THE MANAGEMENT OF PATIENTS WITH CHRONIC PAIN | NCT03319238 | Status not reported | Not reported | 2016-07-07 | University Hospital, Clermont-Ferrand, Clermont-Ferrand |
| Effects of Ketamine in the Acute Phase of Suicidal Ideation | NCT02299440 | Completed | Phase 3 | 2015-04-01 | Centre Hospitalier Universitaire de Nīmes, Clermont-Ferrand |
| Cognitive Biases Under Ketamine | NCT02235012 | Completed | Not applicable | 2014-09-08 | Centre Hospitalier St Anne, Paris |
| Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks | NCT01557712 | Completed | Phase 3 | 2012-03-01 | University Hospital, Grenoble, Grenoble |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | Ketamine
Institution hubs in this country
Institutions in this country with at least 3 counted studies. The number is that institution's own count of studies, which can include studies not shown above if the registry lists them under another country.
- Centre Hospitalier St Anne: 3 studies
- Centre Hospitalier Universitaire de Nīmes: 3 studies
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 12 |
| Suicidal ideation and suicide risk | 3 |
| Treatment-resistant depression | 3 |
| Alcohol use disorder | 2 |
| Anxiety | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | Israel | Brazil | China | Netherlands | Australia | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland